振華股份(603067.SH)完成收購民豐化工100%股權
格隆匯1月12日丨振華股份(603067.SH)公佈,公司已收到中國證監會核發的《關於核准湖北振華化學股份有限公司向重慶化醫控股(集團)公司發行股份購買資產的批覆》,以及國家市場監督管理總局出具的《經營者集中反壟斷審查不予禁止決定書》。
截至本公吿披露日,公司本次發行股份購買資產暨關聯交易之標的資產重慶民豐化工有限責任公司(以下簡稱“民豐化工”)100%股權的過户手續及相關工商變更登記手續已完成,公司現直接持有民豐化工100%的股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.